Treatment of Schizoaffective Disorder Using Mifepristone

This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : Mifepristone

Phase: Phase 2/Phase 3

Eligibility

Ages Eligible For Study:

18 Years - 75 Years

Inclusion Criteria

The subjects will be 30 inpatients or outpatients with schizoaffective disorder.

External Links

Contact information

Primary Contact:

Jessica Hawkins 6507238323

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: